TABLE 1.

Baseline demographics of phase 2B mITT population

	Placebo (N = 68)	NP001 (N = 68)	Total (N = 136)
Male/female, n (%male)	46/22 (67.6%)	45/23 (66.2%)	91/45 (66.9%)
Age in years, mean (SD) a	56.6 (10.75)	57.8 (10.89)	57.2 (10.80)
Months since ALS symptom onset (SD) b	18.83 (8.13)	19.07 (8.40)	18.97(8.23)
Familial/sporadic ALS, n (%familial) c	14/54 (20.6%)	2/66 (2.9%)	16/120 (11.8%)
Bulbar, n (%)	10 (14.7%)	7 (10.3%)	17 (12.5%)
Limbs, n (%)	58 (85.3%)	61 (89.7%)	119 (87.5%)
Concurrent riluzole use, n (%)	45 (66.2%)	45 (66.2%)	90 (66.2%)
ALSFRS‐R score at baseline, mean (SD)	36.7 (5.64)	37.7 (5.07)	37.2 (5.35)
Hs‐CRP at baseline, mg/L, mean (SD)	3.99 (5.49)	4.38 (4.35)	4.18 (4.94)

Abbreviation: N (n), number of participants.

^a Age is calculated relative to the date of informed consent.

^b Months from ALS symptom onset to randomization.

^c Genetic testing information of familial ALS in the Supporting Information Table S1 in the Appendix.